Wed, January 28, 2009
Tue, January 27, 2009
[ Tue, Jan 27th 2009 ] - Market Wire
SCOR: SCOR sets up Zurich Hub
Mon, January 26, 2009
Sun, January 25, 2009
Fri, January 23, 2009
Thu, January 22, 2009
Wed, January 21, 2009
Tue, January 20, 2009
Mon, January 19, 2009
Fri, January 16, 2009
Thu, January 15, 2009
Wed, January 14, 2009
Tue, January 13, 2009
Mon, January 12, 2009
Sun, January 11, 2009
Fri, January 9, 2009

Luminex Corporation Announces Organizational Change


//health-fitness.news-articles.net/content/2009/ .. corporation-announces-organizational-change.html
Published in Health and Fitness on Tuesday, January 20th 2009 at 5:16 GMT, Last Modified on 2009-01-20 05:17:26 by Market Wire   Print publication without navigation


AUSTIN, Texas--([ BUSINESS WIRE ])--Luminex Corporation (NASDAQ:LMNX) today announced the resignation of Douglas C. Bryant, executive vice president and chief operating officer. Mr. Bryant is leaving Luminex to become president and chief executive officer at Quidel Corporation in San Diego, California.

"On behalf of the board of directors, employees and shareholders, I would like to thank Doug for his leadership, hard work and dedication to Luminex," said Patrick J. Balthrop, president and chief executive officer of Luminex. "I am personally grateful for the expertise and leadership Doug has provided and we all wish him every success in his future endeavors.

"We continue to be excited about the growth of Luminex and the success of xMAP® technology in our targeted market segments. We look forward to the opportunities ahead of us in 2009," continued Balthrop.

ABOUT LUMINEX CORPORATION

Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP® system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP® technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex or xMAP® can be obtained on the Internet at [ http://www.luminexcorp.com ].

Statements made in this release that express Luminex' or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements.Factors that could cause Luminex' actual results or performance to differ are detailed under the heading "Risk Factors" in Luminex' Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission.The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


Publication Contributing Sources